These cells exhibit potent, multifaceted antitumor activity against GBM, including direct tumor cell killing via CAR and NK receptors and selective targeting of CD1d<sup>+</sup> immunosuppressive cells within the TME via their invariant T cell receptors. Here, CD1D is linked to glioblastoma.